Actively Recruiting
Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2025-04-09
40
Participants Needed
1
Research Sites
227 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire de Saint Etienne
Lead Sponsor
I
Institut de Cancérologie de la Loire
Collaborating Sponsor
AI-Summary
What this Trial Is About
Chemotherapy or targeted therapy are usually used to treat hematological pathologies. Despite of medical improvement, some of these pathologies present drug resistances, or high risk of relapse. Hematopoietic stem cell (HSC) transplantation remain the gold standard of consolidation, to maintain a durable response. In this situation, allograft with hematopoietic stem cells donor aims at producing Graft-versus-Tumor effect, by producing a new immune system, reproducing anti-tumoral immunity. However, all hemopathies do not have the same sensibility. Nowadays, mechanisms underlying this phenomenon remain poorly understood. Indeed, few data precisely document the expression of immunological checkpoints and other biomarkers in the context of allogeneic HSC transplantation, particularly their impact on post-transplant outcome.
CONDITIONS
Official Title
Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient, over 18 years of age, suffering from a malignant hemopathy (without exception)
- Patient for whom an allogeneic hematopoietic stem cell transplant from a related or unrelated donor is indicated
- Signed informed consent
- Patient covered by a social security scheme
You will not qualify if you...
- Allogeneic hematopoietic stem cell transplantation from cord blood or haplo-identical transplant
- Allogeneic transplant with post-transplant cyclophosphamide treatment
- Allograft with sequential conditioning
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Saint-Etienne
Saint-Etienne, France, 42055
Actively Recruiting
Research Team
J
Jérôme Cornillon, MD
CONTACT
E
Elisabeth Daguenet, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here